Clinical Evaluation of Maintenance BCG Immunotherapy in Superficial Bladder Tumors
BCG maintenance immunotherapy 1/3 dose : 27 mg two randomized arms : 3 or 6 months for 36
months clinical side effects according to OMS score efficacy regarding recurrence : cytology
and cystoscopy PSA, leucocyturia and N-ramp gene evaluation
Observational
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective
Christian PFISTER, MD, PhD
Principal Investigator
Rouen University Hospital
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
2003/081/HP
NCT00213655
Name | Location |
---|